You are here:

Life Sciences

Successfully developing and marketing products in the pharmaceutical and life sciences sectors requires first-rate legal and tax support. This support must include an expert understanding of clinical research, intellectual property, tax planning, regulatory compliance and pricing issues; together with a top-down grasp of how these topics interrelate and influence one another. The team at Loyens & Loeff offers this very support in their broad portfolio of services.

Extension of the wage withholding tax exemption for scientific research personnel

".. Loyens & Loeff’s ‘top-performing’ team advises healthcare providers on regulatory issues, and assists life sciences companies with incorporations and data privacy."- Legal 500

Broad expertise

Our expert team offers you a wide range of services :

  • Regulatory matters, (e.g. marketing authorisation, DMFs, GMP compliance, and manufacturing licences) and pricing & reimbursement;
  • Drafting and negotiating agreements (e.g. clinical trials, licensing, and supply and distribution);
  • Advertising, marketing and product liability (e.g. litigation and insurance);
  • Competition and anti-trust;
  • Corporate and tax structuring (including M&A); and,
  • Transfer pricing, customs, and VAT.

Together with our clients

Our Life Sciences Team works collaboratively with clients ranging from biotech and start-up backgrounds, all the way to global pharmaceutical leaders. These client relationships have provided the team with indispensable market insight, valued by all our clients in this complex sector.

How we work

Our team combines the skills of attorneys, tax advisers and civil law notaries that have extensive experience in the sector. We bring together expertise in commercial, corporate, tax, regulatory, intellectual property, competition, data protection, and employment matters. Combined with monitoring market developments, this allows us to provide advice in a proactive and pragmatic manner, enabling you to capitalise on business opportunities.

Lauxera Capital Partners invests in LUMICKS
Deal - 26 April 2021 - Netherlands

Lauxera Capital Partners invests in LUMICKS

The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners.
read more
Due Diligence For Swiss CBD Companies
Article - 24 March 2021 - Switzerland

Due Diligence for Swiss CBD Companies

Switzerland has proven to provide for attractive conditions for businesses involved in the production and distribution of cannabidiol (CBD) products.
read more
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. next page